Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
Abstract Background Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialys...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-08-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12882-017-0691-6 |
| _version_ | 1818907949024673792 |
|---|---|
| author | Yifeng Xie Peiling Su Yifan Sun Hongsheng Zhang Rong Zhao Liang Li Lanfen Meng |
| author_facet | Yifeng Xie Peiling Su Yifan Sun Hongsheng Zhang Rong Zhao Liang Li Lanfen Meng |
| author_sort | Yifeng Xie |
| collection | DOAJ |
| description | Abstract Background Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patients has been unproven. Methods We searched PubMed, Embase, and the Cochrane Library for the time period through June 2017 to identify randomized controlled trials that evaluated paricalcitol compared with other VDRAs for treatment of SHPT. The primary outcome was the percentage of patients with target reduction of intact parathyroid hormone (iPTH) from baseline. Secondary outcomes included incidences of hypercalcemia and hyperphosphatemia. The random-effects model was used to estimate relative risks (RRs) with 95% confidence intervals (CIs). Results Eight studies (N = 759) were eligible for final inclusion. Compared with other VDRAs, no significant differences were found in the percentage of patients with target reduction of intact parathyroid hormone (iPTH) from baseline for paricalcitol treatment of SHPT in dialysis patients (RR, 1.01; 95% CI, 0. 87–1.18; p = 0.85). There were no differences in the incidence of hypercalcemia (RR, 0.95; 95% CI, 0.74–1.21; p = 0. 65) and hyperphosphatemia (RR, 0.94; 95% CI, 0.77–1.16; p = 0.58). Conclusions The presently available evidence is insufficient to draw a conclusion regarding whether paricalcitol therapy has a comparative efficacy and safety over other VDRAs for treating dialysis patients with SHPT. Large-sample, well-conducted, high-quality RCTs with patient-level outcomes (i.e., mortality) are urgently needed. |
| first_indexed | 2024-12-19T22:03:14Z |
| format | Article |
| id | doaj.art-fbb45297460840798dc93594a7555937 |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-19T22:03:14Z |
| publishDate | 2017-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-fbb45297460840798dc93594a75559372022-12-21T20:04:06ZengBMCBMC Nephrology1471-23692017-08-011811910.1186/s12882-017-0691-6Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trialsYifeng Xie0Peiling Su1Yifan Sun2Hongsheng Zhang3Rong Zhao4Liang Li5Lanfen Meng6Department of Nephrology, The Third Affiliated Hospital of Guangxi University of Chinese medicineDepartment of Nephrology, The Third Affiliated Hospital of Guangxi University of Chinese medicineDepartment of Clinical Laboratory, The Third Affiliated Hospital of Guangxi University of Chinese medicineDepartment of Orthopaedics, The Third Affiliated Hospital of Guangxi University of Chinese medicineDepartment of Nephrology, The Third Affiliated Hospital of Guangxi University of Chinese medicineDepartment of Nephrology, The Third Affiliated Hospital of Guangxi University of Chinese medicineDepartment of Nephrology, The Third Affiliated Hospital of Guangxi University of Chinese medicineAbstract Background Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patients has been unproven. Methods We searched PubMed, Embase, and the Cochrane Library for the time period through June 2017 to identify randomized controlled trials that evaluated paricalcitol compared with other VDRAs for treatment of SHPT. The primary outcome was the percentage of patients with target reduction of intact parathyroid hormone (iPTH) from baseline. Secondary outcomes included incidences of hypercalcemia and hyperphosphatemia. The random-effects model was used to estimate relative risks (RRs) with 95% confidence intervals (CIs). Results Eight studies (N = 759) were eligible for final inclusion. Compared with other VDRAs, no significant differences were found in the percentage of patients with target reduction of intact parathyroid hormone (iPTH) from baseline for paricalcitol treatment of SHPT in dialysis patients (RR, 1.01; 95% CI, 0. 87–1.18; p = 0.85). There were no differences in the incidence of hypercalcemia (RR, 0.95; 95% CI, 0.74–1.21; p = 0. 65) and hyperphosphatemia (RR, 0.94; 95% CI, 0.77–1.16; p = 0.58). Conclusions The presently available evidence is insufficient to draw a conclusion regarding whether paricalcitol therapy has a comparative efficacy and safety over other VDRAs for treating dialysis patients with SHPT. Large-sample, well-conducted, high-quality RCTs with patient-level outcomes (i.e., mortality) are urgently needed.http://link.springer.com/article/10.1186/s12882-017-0691-6ParicalcitolVitamin D receptor activatorSecondary hyperparathyroidism (SHPT)HemodialysisPeritoneal dialysis |
| spellingShingle | Yifeng Xie Peiling Su Yifan Sun Hongsheng Zhang Rong Zhao Liang Li Lanfen Meng Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials BMC Nephrology Paricalcitol Vitamin D receptor activator Secondary hyperparathyroidism (SHPT) Hemodialysis Peritoneal dialysis |
| title | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials |
| title_full | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials |
| title_fullStr | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials |
| title_full_unstemmed | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials |
| title_short | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials |
| title_sort | comparative efficacy and safety of paricalcitol versus vitamin d receptor activators for dialysis patients with secondary hyperparathyroidism a meta analysis of randomized controlled trials |
| topic | Paricalcitol Vitamin D receptor activator Secondary hyperparathyroidism (SHPT) Hemodialysis Peritoneal dialysis |
| url | http://link.springer.com/article/10.1186/s12882-017-0691-6 |
| work_keys_str_mv | AT yifengxie comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials AT peilingsu comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials AT yifansun comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials AT hongshengzhang comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials AT rongzhao comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials AT liangli comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials AT lanfenmeng comparativeefficacyandsafetyofparicalcitolversusvitamindreceptoractivatorsfordialysispatientswithsecondaryhyperparathyroidismametaanalysisofrandomizedcontrolledtrials |